Johnson & Johnson Announces Data From Phase 3 MajesTEC-3 Trial Demonstrates Disease Control, Survival With TECVAYLI Plus DARZALEX FASPRO To Treat Relapsed Or Refractory Multiple Myeloma

Johnson & Johnson (NYSE: JNJ) announced new data from the Phase 3 MajesTEC-3 trial, demonstrating sustained disease control and improved survival rates for patients with relapsed or refractory multiple myeloma when treated with TECVAYLI (teclistamab-cqyv) in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj). The study focused on patients who had previously undergone 1-3 lines of therapy.